Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Non Operating Investment Income (2018 - 2023)

Bioadaptives' Non Operating Investment Income history spans 5 years, with the latest figure at -$11.0 for Q4 2023.

  • On a quarterly basis, Non Operating Investment Income fell 210.0% to -$11.0 in Q4 2023 year-over-year; TTM through Sep 2024 was -$11.0, a 47.62% increase, with the full-year FY2023 number at -$42.0, up 71.62% from a year prior.
  • Non Operating Investment Income hit -$11.0 in Q4 2023 for Bioadaptives, roughly flat from -$11.0 in the prior quarter.
  • Over the last five years, Non Operating Investment Income for BDPT hit a ceiling of $5901.0 in Q4 2019 and a floor of -$2517.0 in Q2 2021.
  • Historically, Non Operating Investment Income has averaged $122.15 across 5 years, with a median of -$26.0 in 2022.
  • The widest YoY moves for Non Operating Investment Income: up 887.22% in 2021, down 621.2% in 2021.
  • Tracing BDPT's Non Operating Investment Income over 5 years: stood at $5901.0 in 2019, then tumbled by 99.1% to $53.0 in 2020, then crashed by 379.25% to -$148.0 in 2021, then skyrocketed by 106.76% to $10.0 in 2022, then crashed by 210.0% to -$11.0 in 2023.
  • Business Quant data shows Non Operating Investment Income for BDPT at -$11.0 in Q4 2023, -$11.0 in Q3 2023, and -$10.0 in Q2 2023.